Insights - In mid-March, Novartis’ combination Tafinlar (dabrafenib) + Mekinist (trametinib) received FDAapproval for pediatric patients with low-grade glioma (pLGG) with a BRAF V600E mutation, the most … Continue Reading
Premium: Read NowInsights - Affimed announced a rather disappointing update yesterday. There was not much clarity shared and it seemed like AFM24 was seeing more data delays. The main … Continue Reading
Premium: Read NowInsights - Yesterday Karuna (KRTX) reported data on the third positive registrational trial, announcing that the trial met its primary endpoint. With three positive registrational trials reported … Continue Reading
Premium: Read NowInsights - The wild weekend was followed by an eventful Monday, especially for the biotech world. The SVB fiasco saw a solution that was a relief for … Continue Reading
Read NowInsights - Silicon Valley Bank’s collapse has caused a ripple amongst the biotech world as the bank did business with about half of American tech and biotech … Continue Reading
Premium: Read NowInsights - Day One’s Drug Ready for NDADay One Pharma (DAWN) is developing tovorafenib (DAY101), an oral pan-RAF inhibitor for pediatric low-grade gliomas (pLGG). Despite being the … Continue Reading
Premium: Read NowInsights - aTyr (LIFE) announced a financing yesterday which diluted the company by approximately 45%. LIFE offered 22.225M shares of stock at a price of $2.25 to raise … Continue Reading
Premium: Read Now
